The story
Founded by Walter Woltosz in 1996.1
SLP on Nasdaq
Simulations Plus
American software company based in Lancaster, founded in 19961
Simulations Plus, Inc. develops absorption, distribution, metabolism, excretion, and toxicity (ADMET) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries. In September 2014, the company acquired Cognigen Corporation, a provider of clinical trial data analysis and consulting services.3 It was founded by Walter Woltosz.1 Its shares trade on Nasdaq under the symbol SLP.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 20, 2026.
Overview
Compare with Pony.ai, CSP INC /MA/ or CREATIVE REALITIES, INC., or pick any stock.
- TickerSLP on Nasdaq1
- Industrysoftware industry1
- HeadquartersLancaster1
- Websitewww.simulations-plus.com
- Business address600 Park Offices Drive, Suite 300 #4134, Durham, Nc 277136
- Filer categoryNon-accelerated filer, Smaller reporting company6
- Legal formStock Corporation4
- LEI529900KYRDJAQ8TJCG934
- StatusActive4
- LEI statusIssued and current4
- Registered addressc/o CSC - LAWYERS INCORPORATING SERVICE, 2710 Gateway Oaks Drive, Suite 150N, 95833 Sacramento, United States4
- Registered withSecretary of State, 17874024
See how the biggest companies compare on our leaderboards
Simulations Plus, Inc. develops absorption, distribution, metabolism, excretion, and toxicity (ADMET) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries. In September 2014, the company acquired Cognigen Corporation, a provider of clinical trial data analysis and consulting services.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
58.4%Gross margin5
-89.3%Operating margin5
-81.7%Net margin5
13.1%Revenue growth, 20255
-51.9%Return on equity5
$17.4MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License and Maintenance brought in 58% of the revenue Simulations Plus broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| License and Maintenance | $36.5M | $41.0M | $45.8M |
| Service | $23.1M | $29.0M | $33.4M |
Business segments
Software brought in 50% of the revenue Simulations Plus broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Software | $36.5M | $41.0M | $45.8M |
| Software | $36.5M | $41.0M | $45.8M |
Regions
Americas brought in 73% of the revenue Simulations Plus broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Americas | $40.8M | $50.5M | $57.7M |
| EMEA | $11.7M | $14.1M | $14.2M |
| Asia Pacific | $7.0M | $5.5M | $7.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue42¢$33.0M
- Research and development9¢$6.9M
- Selling, general and admin26¢$20.9M
- Other costs17¢$13.7M
- Income tax6¢$4.7M
Out of $79.2M in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending4¢$713.0K
- Kept or used elsewhere96¢$17.4M
Out of $18.1M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-08-31 | 2024-08-31 | 2023-08-31 |
|---|---|---|---|
| Revenues | $79.2M | $70.0M | $59.6M |
| Total cost of revenues | $33.0M | $26.9M | $11.6M |
| Gross profit | $46.2M | $43.2M | $47.9M |
| Research and development | $6.9M | $5.8M | $4.5M |
| Sales and marketing | $11.9M | $8.9M | $6.6M |
| General and administrative | $20.9M | $22.4M | $27.7M |
| Impairments | $77.2M | $0 | $500.0K |
| Total operating expenses | $117.0M | $37.0M | $39.2M |
| (Loss) income from operations | -$70.7M | $6.1M | $8.7M |
| Other income, net | $1.4M | $6.3M | $3.0M |
| (Loss) income before income taxes | -$69.4M | $12.4M | $11.7M |
| Income tax benefit (expense) | $4.7M | -$2.5M | -$1.7M |
| Net (loss) income | -$64.7M | $10.0M | $10.0M |
| Basic (in usd per share) | -$3.22 | $0.50 | $0.50 |
| Diluted (in usd per share) | -$3.22 | $0.49 | $0.49 |
| Basic (in shares) | 20.1M shares | 20.0M shares | 20.1M shares |
| Diluted (in shares) | 20.1M shares | 20.3M shares | 20.5M shares |
| Foreign currency translation adjustments | -$24.0K | -$105.0K | $167.0K |
| Unrealized gains (losses) on available-for-sale securities | $4.0K | -$5.0K | $0 |
| Comprehensive (loss) income | -$64.7M | $9.8M | $10.1M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $30.9M | $10.3M | ||
| Accounts receivable, net of allowance for credit losses of $187 and $149 | $9.7M | $9.1M | ||
| Prepaid income taxes | $1.8M | $2.2M | ||
| Prepaid expenses and other current assets | $7.7M | $7.8M | ||
| Short-term investments | $1.5M | $9.9M | ||
| Total current assets | $51.5M | $39.3M | ||
| Capitalized computer software development costs, net of accumulated amortization of $21,863 and $18,727 | $11.1M | $12.5M | ||
| Property and equipment, net | $880.0K | $812.0K | ||
| Operating lease right-of-use assets | $407.0K | $1.0M | ||
| Goodwill | $43.7M | $96.1M | ||
| Deferred tax assets, net | $4.8M | $0 | ||
| Other assets | $1.4M | $542.0K | ||
| Total assets | $131.9M | $196.6M | ||
| Accounts payable | $470.0K | $602.0K | ||
| Accrued compensation | $2.0M | $4.5M | ||
| Accrued expenses | $1.3M | $2.0M | ||
| Contracts payable - current portion | $0 | $2.4M | ||
| Operating lease liability - current portion | $206.0K | $475.0K | ||
| Deferred revenue | $2.7M | $2.0M | ||
| Total current liabilities | $6.7M | $12.1M | ||
| Net deferred tax assets (liabilities) | $0 | $1.6M | ||
| Operating lease liability - net of current portion | $410.0K | $531.0K | ||
| Total liabilities | $7.1M | $14.2M | ||
| Preferred stock, $0.001 par value 10,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | ||
| Common stock, $0.001 par value; 50,000,000 shares authorized, 20,137,480 and 20,051,134 shares issued and outstanding | $20.0K | $20.0K | ||
| Additional paid-in capital | $159.4M | $152.3M | ||
| (Accumulated deficit) retained earnings | -$34.4M | $30.4M | ||
| Accumulated other comprehensive loss | -$271.0K | -$251.0K | ||
| Total shareholders' equity | $124.8M | $182.4M | $170.0M | $178.2M |
| Total liabilities and shareholders' equity | $131.9M | $196.6M | ||
| Accounts receivable, allowance for credit loss, current | $187.0K | $149.0K | ||
| Capitalized computer software, accumulated amortization | $21.9M | $18.7M | ||
| Preferred stock, par or stated value per share (in usd per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par or stated value per share (in usd per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | ||
| Common stock, shares, issued (in shares) | 20.1M shares | 20.1M shares | ||
| Common stock, shares, outstanding (in shares) | 20.1M shares | 20.1M shares |
| Period ending | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $30.9M | $10.3M | ||
| Accounts receivable, net of allowance for credit losses of $187 and $149 | $9.7M | $9.1M | ||
| Prepaid income taxes | $1.8M | $2.2M | ||
| Prepaid expenses and other current assets | $7.7M | $7.8M | ||
| Short-term investments | $1.5M | $9.9M | ||
| Total current assets | $51.5M | $39.3M | ||
| Capitalized computer software development costs, net of accumulated amortization of $21,863 and $18,727 | $11.1M | $12.5M | ||
| Property and equipment, net | $880.0K | $812.0K | ||
| Operating lease right-of-use assets | $407.0K | $1.0M | ||
| Goodwill | $43.7M | $96.1M | ||
| Deferred tax assets, net | $4.8M | $0 | ||
| Other assets | $1.4M | $542.0K | ||
| Total assets | $131.9M | $196.6M | ||
| Accounts payable | $470.0K | $602.0K | ||
| Accrued compensation | $2.0M | $4.5M | ||
| Accrued expenses | $1.3M | $2.0M | ||
| Contracts payable - current portion | $0 | $2.4M | ||
| Operating lease liability - current portion | $206.0K | $475.0K | ||
| Deferred revenue | $2.7M | $2.0M | ||
| Total current liabilities | $6.7M | $12.1M | ||
| Net deferred tax assets (liabilities) | $0 | $1.6M | ||
| Operating lease liability - net of current portion | $410.0K | $531.0K | ||
| Total liabilities | $7.1M | $14.2M | ||
| Preferred stock, $0.001 par value 10,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | ||
| Common stock, $0.001 par value; 50,000,000 shares authorized, 20,137,480 and 20,051,134 shares issued and outstanding | $20.0K | $20.0K | ||
| Additional paid-in capital | $159.4M | $152.3M | ||
| (Accumulated deficit) retained earnings | -$34.4M | $30.4M | ||
| Accumulated other comprehensive loss | -$271.0K | -$251.0K | ||
| Total shareholders' equity | $124.8M | $182.4M | $170.0M | $178.2M |
| Total liabilities and shareholders' equity | $131.9M | $196.6M | ||
| Accounts receivable, allowance for credit loss, current | $187.0K | $149.0K | ||
| Capitalized computer software, accumulated amortization | $21.9M | $18.7M | ||
| Preferred stock, par or stated value per share (in usd per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par or stated value per share (in usd per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | ||
| Common stock, shares, issued (in shares) | 20.1M shares | 20.1M shares | ||
| Common stock, shares, outstanding (in shares) | 20.1M shares | 20.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-08-31 | 2024-08-31 | 2023-08-31 |
|---|---|---|---|
| Net (loss) income | -$64.7M | $10.0M | $10.0M |
| Depreciation and amortization | $8.2M | $5.7M | $3.8M |
| Change in fair value of contingent consideration | -$640.0K | -$1.6M | $680.0K |
| Discharge of holdback obligation related to Immunetrics acquisition | -$224.0K | $0 | $0 |
| Amortization of investment discounts | -$64.0K | -$1.1M | -$1.1M |
| Stock-based compensation | $6.4M | $6.5M | $4.8M |
| Deferred income taxes | -$5.4M | -$1.8M | -$2.1M |
| Loss from disposal of assets | $23.0K | $0 | $6.0K |
| Impairments | $77.2M | $0 | $500.0K |
| Currency translation adjustments | -$25.0K | -$105.0K | $167.0K |
| Accounts receivable | -$581.0K | $3.1M | $4.1M |
| Prepaid income taxes | $420.0K | -$1.4M | $587.0K |
| Prepaid expenses and other assets | $194.0K | -$2.1M | -$501.0K |
| Accounts payable | -$132.0K | -$477.0K | -$81.0K |
| Other liabilities | -$3.2M | -$768.0K | $832.0K |
| Accrued income taxes | $0 | $0 | -$7.0K |
| Deferred revenue | $700.0K | -$2.6M | $176.0K |
| Net cash provided by operating activities | $18.1M | $13.3M | $21.9M |
| Purchases of property and equipment | -$713.0K | -$566.0K | -$453.0K |
| Purchase of short-term investments | -$6.5M | -$67.2M | -$95.0M |
| Proceeds from maturities of short-term investments | $14.0M | $71.1M | $114.9M |
| Proceeds from sales of investments | $995.0K | $45.2M | $0 |
| Issuance of promissory note | -$1.0M | $0 | $0 |
| Purchased intangibles | -$379.0K | -$541.0K | -$601.0K |
| Business acquisition, net of cash acquired | $0 | -$98.8M | -$8.2M |
| Net working capital & excess cash settlement - Pro-ficiency acquisition | -$227.0K | $0 | $0 |
| Capitalized computer software development costs | -$2.6M | -$3.2M | -$3.2M |
| Net cash used in investing activities | $3.6M | -$54.0M | $7.4M |
| Payment of dividends | $0 | -$4.8M | -$4.8M |
| Payments on contracts payable | -$1.6M | -$2.5M | $0 |
| Proceeds from the exercise of stock options | $430.0K | $731.0K | $1.5M |
| Repurchase and retirement of common shares | $0 | $0 | -$20.0M |
| Net cash used in financing activities | -$1.1M | -$6.6M | -$23.3M |
| Net increase (decrease) in cash and cash equivalents | $20.5M | -$47.2M | $6.0M |
| Income taxes paid | $1.2M | $5.7M | $3.2M |
| Measurement period adjustments (See Note 2) | $956.0K | $0 | $0 |
| Creation of contract liabilities from acquisition of subsidiaries | $0 | $0 | $5.9M |
| Right of use assets capitalized | $426.0K | $212.0K | $227.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Simulations Plus sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Simulations Plus
- First Eagle Investment Management, LLC Filed SCHEDULE 13G on Simulations Plus, latest Aug 6, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Simulations Plus, latest Mar 27, 2026 (6 filings since Feb 10, 2022)
- First Light Asset Management, LLC Filed SCHEDULE 13G on Simulations Plus, latest Feb 6, 2026
- BlackRock Filed SCHEDULE 13G/A on Simulations Plus, latest Oct 2, 2025
- Conestoga Capital Advisors, LLC Filed SCHEDULE 13G on Simulations Plus, latest Jan 10, 2025 (4 filings since Jan 10, 2022)
- Neuberger Berman Filed SC 13G/A on Simulations Plus, latest Aug 8, 2024 (4 filings since Feb 11, 2022)
- Simulations Plus Sacramento, California, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Simulations Plus reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Computer equipment and software | $3.3M11 Aug 31, 2024 | $3.3M11 Aug 31, 2023 | 0% |
| Property and equipment, before depreciation | $1.5M5 Aug 31, 2025 | $1.4M5 Aug 31, 2024 | +3.0% |
| Accumulated depreciation | $577.0K5 Aug 31, 2025 | $603.0K5 Aug 31, 2024 | −4.3% |
| Property and equipment, net | $880.0K5 Aug 31, 2025 | $812.0K5 Aug 31, 2024 | +8.4% |
| Operating-lease assets (leased space) | $407.0K5 Aug 31, 2025 | $1.0M5 Aug 31, 2024 | −60.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $30.9M5 Aug 31, 2025 | $10.3M5 Aug 31, 2024 | +199.2% |
| Marketable securities, current | $1.5M5 Aug 31, 2025 | $9.9M5 Aug 31, 2024 | −84.9% |
Intangibles and goodwill
Properties, in its own words
The Company was previously headquartered in Southern California; however, in support of the Company's remote work culture and plan to reduce excess office space to achieve its carbon footprint reduction targets, the Company fully exited four office locations in Lancaster, California; Raleigh, North Carolina; Buffalo, New York; and Pittsburgh, Pennsylvania. As a result, the company moved its headquarters from Lancaster, California, to Research Triangle Park, North Carolina, and also maintains a European office in Paris, France. We do not believe that any of the physical properties that we lease are material to our business.
Item 2 of the 10-K filed Dec 1, 2025.16
Leadership
Who has led Simulations Plus, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
200020052010201520202025
- FounderWalter Woltosz1
- Chief executive officerShawn Oconnor Jul 6, 2018 to now17
- Chief executive officerWalter Woltosz Aug 1, 2006 to May 30, 201818
- ChairWalter Woltosz Aug 1, 2006 to Aug 28, 201818
- PresidentMichael E. Raymer Jun 21, 2024 to Jun 21, 202419
- PresidentBrett Howell Dec 16, 2021 to Oct 23, 202320
- PresidentJill Fiedler-Kelly Dec 16, 2021 to Jun 21, 202421
- PresidentThaddeus Henry Grasela Jr. Sep 4, 2014 to Mar 13, 201822
- PresidentWalter Woltosz Dec 19, 2011 to Dec 19, 201123
- PresidentJeffrey A. Dahlen Jul 24, 2006 to Apr 9, 200924
- Chief financial officerWilliam W. Frederick Dec 2, 2020 to now25
- Chief financial officerJohn Robert Kneisel Nov 27, 2013 to Apr 20, 202026
- Chief financial officerMomoko A. Beran Mar 21, 2006 to Feb 21, 201227
- Chief operating officerWilliam W. Frederick Oct 21, 2024 to Oct 21, 202428
Board members and other officers (16)
- Chief Revenue OfficerDaniel Szot Jan 12, 2024 to Oct 21, 202429
- VP of Human ResourcesNguyen Nguyen May 3, 2021 to May 3, 202130
- COWalter Woltosz Sep 29, 2017 to Oct 30, 201731
- Vice President, MarketingRonald F. Creeley Jan 24, 2007 to Jun 19, 200932
- Secretary TreasurerVirginia E. Woltosz Aug 1, 2006 to Jun 28, 201933
- Board memberSharlene Evans Dec 15, 2021 to now34
- Board memberLisa Lavange May 6, 2019 to now35
- Board memberDaniel L. Weiner Aug 2, 2017 to now36
- Board memberThaddeus Henry Grasela Jr. Sep 4, 2014 to Mar 13, 201822
- Board memberJohn Kenneth Paglia Dec 12, 2014 to now37
- Board memberDavid L. Ralph Mar 2, 2012 to Nov 30, 202138
- Board memberWalter Woltosz Dec 2, 2010 to now39
- Board memberHarold Wayne Rosenberger Jan 9, 2008 to Jan 9, 201540
- Board memberVirginia E. Woltosz Aug 1, 2006 to Aug 31, 202133
- Board memberRichard R. Weiss Sep 11, 2006 to Feb 27, 201241
- Board memberArgenio David Z. D. Sep 14, 2006 to Dec 1, 201642
Products and brands
- software
Listed on Wikidata.1
Former names
- SIMULATIONS PLUS INCDec 26, 1996 to Feb 2, 20216
Timeline
- Oct 6, 20268-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights43
- Aug 28, 20268-K Shareholder vote44
- Aug 13, 20268-K Other events45
- Jul 9, 20268-K Results of operations; Regulation FD disclosure46
- Jun 17, 20268-K Entered a material agreement; Executive or director change47
- Jun 16, 20268-K Regulation FD disclosure48
- Apr 9, 20268-K Results of operations; Regulation FD disclosure49
- Feb 18, 20268-K Executive or director change; Shareholder vote50
- Jan 8, 20268-K Results of operations; Regulation FD disclosure51
- Dec 8, 20258-K Entered a material agreement; Executive or director change52
- Dec 1, 20258-K Results of operations; Regulation FD disclosure53
- Oct 22, 20258-K Results of operations; Regulation FD disclosure54
- Jul 6, 2018New chief executive Shawn Oconnor becomes CEO17
- Aug 1, 2006New chief executive Walter Woltosz becomes CEO18
- Jun 19, 1997Went public Listed on NASDAQ1
- 1996Founded Founded1
Calendar
When it reported results
- Jul 9, 2026Reported quarterly or annual results46
- Apr 9, 2026Reported quarterly or annual results49
- Jan 8, 2026Reported quarterly or annual results51
- Dec 1, 2025Reported quarterly or annual results53
- Oct 22, 2025Reported quarterly or annual results54
- Jul 14, 2025Reported quarterly or annual results55
- Jun 12, 2025Reported quarterly or annual results56
- Apr 3, 2025Reported quarterly or annual results57
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
370 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 58 major events, 210 insider forms, 21 large holders, 61 other. The latest 20:
- Oct 7, 2026EFFECT EDGAR
- Oct 7, 2026S-8 POS EDGAR
- Oct 7, 2026S-8 POS EDGAR
- Oct 7, 2026S-8 POS EDGAR
- Oct 7, 2026S-8 POS EDGAR
- Oct 7, 2026S-8 POS EDGAR
- Oct 6, 202625-NSE EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 2026POS AM EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 20268-K EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 20264 EDGAR
- Aug 28, 20268-K EDGAR
- Aug 21, 2026DEFA14A EDGAR
The 370 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
89 open-market trades by officers, directors and large owners since October 2021: 0 buys and 89 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | DiBella John Anthony IIChief Revenue Officer | Sale | 1,000 | $18.28 | $18.3K | Form 4 |
| Jul 6, 2026 | DiBella John Anthony IIChief Revenue Officer | Sale | 1,000 | $18.36 | $18.4K | Form 4 |
| Jul 1, 2026 | WOLTOSZ VIRGINIA E10% owner | Sale | 4,177 | $18.44 | $77.0K | Form 4 |
| Jun 16, 2026 | Fiedler-Kelly JillPresident, Services Solutions | Sale | 7,350 | $18.20 | $133.8K | Form 4 |
| Jun 15, 2026 | Fiedler-Kelly JillPresident, Services Solutions | Sale | 1,050 | $16.51 | $17.3K | Form 4 |
| Jun 3, 2026 | DiBella John Anthony IIChief Revenue Officer | Sale | 1,000 | $16.50 | $16.5K | Form 4 |
| Jun 1, 2026 | WOLTOSZ VIRGINIA E10% owner | Sale | 15,000 | $17.43 | $261.4K | Form 4 |
| May 11, 2026 | Fiedler-Kelly JillPresident, Services Solutions | Sale | 1,000 | $16.53 | $16.5K | Form 4 |
| May 4, 2026 | DiBella John Anthony IIChief Revenue Officer | Sale | 1,000 | $14.98 | $15.0K | Form 4 |
| May 4, 2026 | WOLTOSZ WALTER SDirector | Sale | 15,000 | $15.13 | $226.9K | Form 4 |
| Apr 15, 2026 | DiBella John Anthony IIChief Revenue Officer | Sale | 1,000 | $13.37 | $13.4K | Form 4 |
| Dec 1, 2025 | LaVange LisaDirector | Sale | 866 | $16.91 | $14.6K | Form 4 |
| Oct 1, 2025 | WOLTOSZ VIRGINIA E10% owner | Sale | 20,000 | $15.39 | $307.8K | Form 4 |
| Sep 2, 2025 | LaVange LisaDirector | Sale | 867 | $14.10 | $12.2K | Form 4 |
| Aug 1, 2025 | LaVange LisaDirector | Sale | 867 | $12.93 | $11.2K | Form 4 |
| Jul 1, 2025 | WOLTOSZ WALTER SDirector | Sale | 20,000 | $18.33 | $366.6K | Form 4 |
| Jun 2, 2025 | WOLTOSZ VIRGINIA E10% owner | Sale | 20,000 | $27.15 | $543.1K | Form 4 |
| May 1, 2025 | WOLTOSZ VIRGINIA E10% owner | Sale | 20,000 | $33.51 | $670.1K | Form 4 |
| Apr 1, 2025 | WOLTOSZ WALTER SDirector | Sale | 20,000 | $24.09 | $481.8K | Form 4 |
| Mar 3, 2025 | WOLTOSZ VIRGINIA E10% owner | Sale | 20,000 | $28.68 | $573.6K | Form 4 |
All 89 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- First Eagle Investment Management, LLCSCHEDULE 13G, 1 filing Aug 6, 202658
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 202659
- First Light Asset Management, LLCSCHEDULE 13G, 1 filing Feb 6, 202660
- BlackRockSCHEDULE 13G/A, 1 filing Oct 2, 202561
- Conestoga Capital Advisors, LLCSCHEDULE 13G, 4 filings Jan 10, 2022 to Jan 10, 202562
- Neuberger BermanSC 13G/A, 4 filings Feb 11, 2022 to Aug 8, 202463
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Shawn O’ConnorChief Executive Officer | 66 | $524.7K | $1.1M64 |
| 2025 | Daniel SzotFormer Chief Revenue Officer | $260.7K | $559.9K64 | |
| 2025 | Will FrederickExecutive Vice President & Chief Financial Officer | 62 | $344.1K | $534.7K64 |
| 2025 | John DiBellaChief Revenue Officer | 46 | $344.1K | $489.0K64 |
| 2025 | Steven ChangGlobal Head of Strategic Alliances | $336.4K | $482.3K64 | |
| 2025 | Jill Fiedler-KellyPresident Services Solutions | 57 | $320.7K | $465.1K64 |
| 2025 | Josh FoheyChief Operating Officer | 43 | $264.1K | $358.3K64 |
| 2024 | Shawn O’ConnorChief Executive Officer | 66 | $511.6K | $1.7M64 |
| 2024 | Will FrederickExecutive Vice President & Chief Financial Officer | 62 | $335.4K | $1.0M64 |
| 2024 | Daniel SzotFormer Chief Revenue Officer | $215.8K | $895.1K64 | |
| 2024 | John DiBellaChief Revenue Officer | 46 | $335.4K | $661.6K64 |
| 2024 | Steven ChangGlobal Head of Strategic Alliances | $330.0K | $656.4K64 | |
| 2024 | Jill Fiedler-KellyPresident Services Solutions | 57 | $312.6K | $609.4K64 |
| 2023 | Shawn O’ConnorChief Executive Officer | 66 | $487.5K | $1.9M64 |
| 2023 | Will FrederickExecutive Vice President & Chief Financial Officer | 62 | $319.6K | $880.9K64 |
| 2023 | John DiBellaChief Revenue Officer | 46 | $319.6K | $728.1K64 |
| 2023 | Jill Fiedler-KellyPresident Services Solutions | 57 | $297.9K | $722.1K64 |
| 2023 | Steven ChangGlobal Head of Strategic Alliances | $68.7K | $238.6K64 |
SEC filer profile
How Simulations Plus is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSimulations Plus, Inc.2
- CIK0001023459
- Employer ID (EIN)95-459560916
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company16
- Incorporated inCalifornia16
- Fiscal year endsAugust 312
- Industry code (SIC)7373 Services-Computer Integrated Systems Design2
- SEC reviewing officeOffice of Technology, Division of Corporation Finance2
- Business address600 Park Offices Drive, Suite 300 #4134, Durham, NC 277132
- Phone661-723-77232
- Shares outstanding20,224,838 as of Jun 30, 202613
- Public float$478.9M as of Feb 28, 202516
- AuditorRose, Snyder & Jacobs LLP, Encino, California PCAOB ID 468; no auditor attestation of internal control over financial reporting16
- On EDGAR sinceNov 1, 19962
- Filings1,187 in all: 4 (570), 8-K (254), 10-Q (54), 10QSB (34), 144 (34), DEF 14A (27), 4/A (24), 10-K (17)2
All 50 form types
SC 13G/A (17), 3 (16), PRE 14A (13), 10KSB (12), UPLOAD (11), DEFA14A (10), PRER14A (9), CORRESP (8), 8-K/A (7), S-8 POS (7), NT 10-K (6), S-8 (6), NT 10-Q (5), SC 13G (5), SCHEDULE 13G (4), 10KSB/A (3), SCHEDULE 13G/A (3), 10-K/A (2), 424B5 (2), 8-A12B (2), 8-A12G (2), ARS (2), SB-2/A (2), 10-Q/A (1), 25 (1), 25-NSE (1), 424B1 (1), 424B4 (1), 5 (1), 8-A12G/A (1), CERTAMX (1), CERTNAS (1), DEFM14A (1), DEFR14A (1), EFFECT (1), NT 10-K/A (1), POS AM (1), PRE 14C (1), PREM14A (1), RW (1), S-3 (1), S-3ASR (1)
- Latest filingsAnnual report (10-K) Dec 1, 2025
Quarterly report (10-Q) Jul 9, 2026
Proxy statement (DEF 14A) Dec 29, 2025
Latest 8-K (8-K) Oct 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | SLP | NASDAQ |
From the cover page of the 10-K filed Dec 1, 2025 (Section 12(b) of the Exchange Act).16
Risk factors and legal proceedings
The risks Simulations Plus names in Item 1A of its 10-K filed Dec 1, 2025: 49 risks under these headings, as written.16
- Certain Risks Related to Our Marketplace and Environment
- Our ability to sustain or increase revenues will depend upon our success in entering new markets, continuing to increase our client base, and in deriving additional revenues from our existing clients.
- A decrease in, or resistance to, the acceptance of model-informed drug development and development by regulatory authorities or academic institutions could damage our reputation or reduce the demand for our products and services.
- Increasing competition and increasing costs within the pharmaceutical and biotechnology industries, drug development and services industry, and the life science market for modeling and simulation software and cheminformatics products may affect the demand for our products and services, which may affect our results of operations and financial condition.
- Health care reform and restrictions on reimbursement may affect the pharmaceutical, biotechnology, and industrial chemical companies that purchase or license our products or services, which may affect our results of operations and financial condition.
- We face strong competition in the life science market for modeling and simulation software and for cheminformatics products.
- We are subject to price pressures in the markets we serve.
- Our insurance coverage may not be sufficient to avoid material impact on our financial position or results of operations resulting from claims or liabilities against us, and we may not be able to obtain insurance coverage in the future.
- Any negative commentaries made by any regulatory agencies or any failure by us to comply with applicable regulations and related guidance could harm our reputation and operating results, and compliance with new regulations and guidance may result in additional costs.
- Our sales cycle is lengthy, and clients may delay entering into contracts or decide not to adopt our products or solutions after we have expended significant time and resources and supported evaluation by them of our technology, which could result in delays in recognizing revenue and negatively impact our results of operations.
- Many of our contracts are fixed price and may be delayed or terminated or reduced in scope for reasons beyond our control, or we may underprice or overrun cost estimates with these contracts, potentially resulting in financial losses.
- Impairment of goodwill or intangible assets may adversely impact future results of operations.
The other 37 risks
- Certain Risks Related to Our Operations
- Delays in the release of new or enhanced products or services or undetected errors in our products or services may result in increased cost to us, delayed market acceptance of our products, and delayed or lost revenue.
- We are subject to various risks associated with the operation of a global business.
- Changes in applicable U.S. and international tax laws or regulations and the resolution of tax disputes could negatively affect our financial results.
- Contract research services create a risk of liability.
- The drug discovery and development industry has a history of patent and other intellectual property litigation, involvement in intellectual property lawsuits is often very costly.
- We may not be able to successfully develop and market new services and products.
- We depend on key personnel and may not be able to retain these employees or recruit additional qualified personnel, which could harm our business.
- If we are not successful in selecting and integrating the businesses and technologies we acquire, or in managing our current and future divestitures, our business may suffer.
- Our quarterly and annual operating results fluctuate and may continue to fluctuate in the future, and if we fail to meet the expectations of analysts or investors, our stock price and the value of your investment could decline substantially.
- We conduct business outside the U.S., which exposes us to foreign currency exchange rate risk, amongst other risk, and could have a negative impact on our financial results.
- A significant portion of our operating expenses are relatively fixed and planned expenditures are based in part on expectations regarding future revenues.
- If our clients cancel their contracts or terminate or delay their clinical trials, we may lose or delay revenues and our business may be adversely impacted.
- If our security is breached, our business could be disrupted, our operating results could be harmed, and clients could be deterred from using our products and services.
- Changes in and/or failure to comply with applicable data privacy laws, regulations, and interpretations of such laws and regulations could materially adversely affect our reputation, market position, or our business and financial performance.
- We rely upon a single internal hosting facility and Amazon Web Services to deliver certain solutions to our clients and any disruption of or interference with our hosting systems, operations, or use of the Amazon Web Services could harm our business and results of operations.
- We rely on third-party cloud infrastructure and related services to deliver and operate our software platforms, and any disruption, limitation, or change in these cloud services could adversely affect our business, financial condition, and
- results of operations.
- Defects or errors in our software applications could harm our reputation, result in significant cost to us and impair our ability to market our solutions.
- If we are not able to reliably meet our data storage and management requirements, or if we experience any failure or interruption in the delivery of our services over the Internet, client satisfaction and our reputation could be harmed, and client contracts may be terminated.
- Some of our software solutions and services utilize open-source software, and any failure to comply with the terms of one or more of these open-source licenses could adversely affect our business.
- We may be unable to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights.
- Current and future litigation against us, which may arise in the ordinary course of our business, could be costly and time-consuming to defend.
- We could incur substantial costs resulting from product liability claims relating to our products or services or our clients’ use of our products or services.
- Our business depends on the clinical trial market, and a downturn in this market could cause our revenues to decrease.
- As a public company, we are obligated to maintain proper and effective internal control over financial reporting. As our business expands both organically and through acquisitions, we may be unable to effectively adapt our current systems to our changing business needs and may fail to develop and maintain an effective system of disclosure controls and internal control over financial reporting which could impair our ability to produce timely and accurate financial statements or comply with applicable laws and regulations.
- Certain Risks Related to Ownership of Our Common Stock
- We have discontinued the quarterly dividends on shares of our common stock and do not expect to pay any cash dividends for the foreseeable future.
- If our operating and financial performance in any given period does not meet any guidance that we provide to the public, the market price of our common stock may decline.
- The price of our common stock may be volatile, and our shareholders may not be able to resell shares of our common stock at or above the price they paid.
- If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
- We may raise capital through the issuance of our common stock, convertible debt, or equity-linked securities, which could result in dilution to our shareholders or a negative impact on the price of our common stock.
- We cannot guarantee that our share repurchase program will be fully consummated or that it will enhance long-term
- shareholder value, and share repurchases could increase the volatility of the price of our common stock.
- Risks Relating to Artificial Intelligence and Machine Learning
- The use of AI in our products and services may result in reputational harm and competitive harm.
- Our use of artificial intelligence and machine learning may result in legal and regulatory risks.
- Risks Relating to Government Regulation
- We receive government assistance in the form of cash grants. The interruption of or termination or failure to fund one or more of these grants, or other actions taken by Department of Government Efficiency (“DOGE”) could have an adverse impact on our business, financial condition, results of operations and cash flows.
- Risk Relating to a Federal Government Shutdown
- Changes in government regulation, funding or in practices relating to the pharmaceutical or biotechnology industries, including potential health care reform, could decrease the need for the services we provide.
Legal proceedings
We may become subject to litigation, claims, investigations, and audits arising from time to time in the ordinary course of our business. Management believes that there is no pending or threatened litigation to which the Company and any of its subsidiaries, or any of the Company or its subsidiaries’ properties, is the subject of or party to, which, individually or in the aggregate, would have a material adverse effect on our business, results of operations, financial condition and/or cash flows.
The opening of Item 3, Legal Proceedings.16
Links
- Websitewww.simulations-plus.com1
- WikipediaSimulations Plus
- WikidataQ7521341
- SEC EDGARCIK 1023459
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataSimulations Plus on Wikidata
- 2
- 3WikipediaSimulations Plus on Wikipedia
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19SEC EDGARMichael E. Raymer, President
- 20SEC EDGARBrett Howell, President
- 21SEC EDGARJill Fiedler-Kelly, President
- 22
- 23SEC EDGARWalter Woltosz, President
- 24SEC EDGARJeffrey A. Dahlen, President
- 25
- 26
- 27
- 28
- 29SEC EDGARDaniel Szot, Chief Revenue Officer
- 30SEC EDGARNguyen Nguyen, VP of Human Resources
- 31SEC EDGARWalter Woltosz, CO
- 32
- 33
- 34SEC EDGARSharlene Evans, Board member
- 35SEC EDGARLisa Lavange, Board member
- 36SEC EDGARDaniel L. Weiner, Board member
- 37SEC EDGARJohn Kenneth Paglia, Board member
- 38SEC EDGARDavid L. Ralph, Board member
- 39SEC EDGARWalter Woltosz, Board member
- 40
- 41SEC EDGARRichard R. Weiss, Board member
- 42SEC EDGARArgenio David Z. D., Board member
- 43
- 44SEC EDGARShareholder vote
- 45SEC EDGAROther events
- 46
- 47
- 48SEC EDGARRegulation FD disclosure
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64